BackInsulet Overview
Insulet Corporation

Insulet Target Price

Analysts' average 12-month price target for Insulet is $190.

Get informed when a big investor buys or sells

+ Follow

Share Price

$131.69

Average Target Price

$187.5942.4% upside

17 analysts in the last 4 months

High: $245 | Low: $144

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-06Robert W. BairdJeff Johnson$17532.9% upsideOpen
2026-08-06Bernstein$17532.9% upsideOpen
2026-08-06Leerink PartnersMike Kratky$14510.1% upsideOpen
2026-08-06RBC Capital$16021.5% upsideOpen
2026-08-06Raymond JamesJayson Bedford$18036.7% upsideOpen
2026-08-06Canaccord GenuityWilliam Plovanic$17935.9% upsideOpen
2026-08-05Wells FargoLarry Biegelsen$1449.3% upsideOpen
2026-08-05Truist Financial$15316.2% upsideOpen
2026-07-28UBS$17432.1% upsideOpen
2026-07-13Truist Financial$21059.5% upsideOpen
2026-07-13RBC Capital$24586% upsideOpen
2026-07-10Stifel Nicolaus$22570.9% upsideOpen
2026-07-06Evercore ISI$18036.7% upsideOpen
2026-06-23Deutsche Bank$19044.3% upsideOpen
2026-06-11UBS$21966.3% upsideOpen
2026-06-11Truist FinancialRichard Newitter$21966.3% upsideOpen
2026-06-08Raymond James$21664% upsideOpen
2026-05-27Goldman SachsDavid Roman$20555.7% upsideOpen
2026-05-26BTIG$23578.4% upsideOpen
2026-05-07Goldman Sachs$23780% upsideOpen
2026-05-07RBC CapitalShagun Singh$280112.6% upsideOpen
2026-05-07Truist FinancialRichard Newitter$25089.8% upsideOpen
2026-05-07Evercore ISI$20051.9% upsideOpen
2026-05-07Oppenheimer$21059.5% upsideOpen
2026-05-07Stifel Nicolaus$25089.8% upsideOpen
2026-05-07Canaccord GenuityWilliam Plovanic$24989.1% upsideOpen
2026-05-07Bernstein$20051.9% upsideOpen
2026-05-07BarclaysMatt Miksic$19850.4% upsideOpen
2026-05-06BTIG$26097.4% upsideOpen
2026-04-24Redburn Partners$22067.1% upsideOpen
2026-04-15Truist FinancialRichard Newitter$315139.2% upsideOpen
2026-04-14RBC CapitalShagun Singh$325146.8% upsideOpen
2026-02-19Truist Financial$360173.4% upsideOpen
2026-02-19Evercore ISI$340158.2% upsideOpen
2026-02-19Goldman SachsDavid Roman$326147.6% upsideOpen
2026-02-19Oppenheimer$300127.8% upsideOpen
2026-02-19Bernstein$330150.6% upsideOpen
2026-02-19Barclays$286117.2% upsideOpen
2026-02-18Canaccord GenuityWilliam Plovanic$435230.3% upsideOpen
2026-02-04Stifel Nicolaus$350165.8% upsideOpen
2026-01-12Barclays$274108.1% upsideOpen
2026-01-09BernsteinLee Hambright$380188.6% upsideOpen
2026-01-09Goldman SachsDavid Roman$365177.2% upsideOpen
2025-12-18Truist Financial$390196.2% upsideOpen
2025-12-17Canaccord Genuity$450241.7% upsideOpen
2025-12-16Evercore ISI$370181% upsideOpen
2025-11-24Canaccord Genuity$432228% upsideOpen
2025-11-21Truist FinancialRichard Newitter$412212.9% upsideOpen
2025-11-21RBC CapitalShagun Singh$380188.6% upsideOpen
2025-11-21BTIG$380188.6% upsideOpen

Insulet (PODD) FAQ

As of the most recent data, PODD shows a target price of $190. Scroll down for historical charts and peer comparison views.

If Insulet moved to the average analyst target of $190, shares would be roughly 42.4% higher than $131.69. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Insulet's earnings trajectory.

Besides this target price page, Stockcircle has Insulet's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $190) with ownership activity and broader fundamentals.

Insulet's target price is $190; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.